Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0154 • ACR Convergence 2023
Impact of Social Determinants of Health (SDoH) on Survey Response Times Among Lupus Patients
Daniel Bao¹, Charmayne Dunlop-Thomas², Cristina Drenkard² and S. Sam Lim², ¹Johns Creek High School, Johns Creek, GA, ²Emory University, Atlanta, GA
Background/Purpose: Social determinants of health (SDoH) significantly impact outcomes of Systemic lupus erythematosus (SLE) patients. However, little is known about the influence of SDoH on…
Abstract Number: 0193 • ACR Convergence 2023
Social Vulnerability Associations with Mortality in a Lupus Cohort
Sean Carter¹, Dulaney Wilson¹, Samantha Minkin², David Dillon³, Baxter Murray¹, John Pearce¹ and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, ²Vanderbilt University Medical Center, Nashville, TN, ³Rheumatology Associates of South Florida, Delray Beach, FL
Background/Purpose: The goal of this study is to identify characteristics of socially vulnerable environments associated with increased mortality in a South Carolina systemic lupus erythematosus…
Abstract Number: 0547 • ACR Convergence 2023
A Spatially-resolved Single Cell Resolution Atlas of Pediatric Lupus Nephritis Uncovers Complex Interactions Between Stromal and Infiltrating Immune Cells
Shaun Jackson¹, Nicholas Hasle², Elizabeth Nguyen³, Robyn Reed² and Patrick Danaher⁴, ¹Seattle Children's Research Institute / University of Washington, Seattle, WA, ²Seattle Children's Hospital/University of Washington, Seattle, WA, ³Seattle Children's Research Institute, Seattle, WA, ⁴Nanostring, Inc., Seattle, WA
Background/Purpose: The molecular and cellular heterogeneity of human Lupus Nephritis (LN) at the kidney tissue level makes it challenging to identify key disease drivers and…
Abstract Number: 0564 • ACR Convergence 2023
Risk Factors for Immune Thrombocytopenia in Systemic Lupus Erythematosus and Generation of a Predictive Model to Assess Its Risk of Development
Irene Carrión-Barberà¹, Jesús Cornudella Lema², Sergio Vázquez Montes de Oca³, Francesc García Pallarols¹, Jordi Monfort¹, Blanca Sánchez-González¹ and TAREK CARLOS SALMAN MONTE⁴, ¹Hospital del Mar, Barcelona, Spain, ²Faculty of Medicine, Pompeu Fabra University, Barcelona, Spain and Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain, ³Biomedical Informatics Research Group, IMIM, Barcelona, Spain, ⁴Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a wide variety of manifestations including immune thrombocytopenia (ITP), which has been described in 7-40%…
Abstract Number: 0582 • ACR Convergence 2023
Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial
Vibeke Strand¹, Kenneth Kalunian², Barnabas Desta³, Caroline Seo⁴, Gabriel Abreu⁵, Raj Tummala³, Catharina Lindholm⁵ and Hussein Al-Mossawi⁶, ¹Stanford University, Palo Alto, CA, ²University of California San Diego, La Jolla, CA, ³BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁴BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: SLE is a chronic disease that progressively reduces patients’ health-related quality of life.1 In a post hoc analysis of the TULIP trials, patients with…
Abstract Number: 0599 • ACR Convergence 2023
Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes
Ana Kunzler¹, Meenakshi Jha¹, Masataka Umeda², Rhea Bhargava², Maria Tsokos¹, George Tsokos² and Abhigyan Satyam², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that leads to damage to several tissues and organs. Inflammation of the kidney is one…
Abstract Number: 0783 • ACR Convergence 2023
Tolerability of CAR T Cell Therapy in Autoimmune Disease
Jule Taubmann¹, Fabian Müller², Michael Aigner³, Ioanna Minopoulou⁴, Johannes Knitza⁵, Dagmar Werner⁶, Christina Bergmann⁷, Gerhard Kroenke⁸, Andreas Mackensen³ and Georg Schett⁶, ¹Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ⁵Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶FAU Erlangen-Nürnberg, Erlangen, Germany, ⁷Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁸Charite Berlin, Berlin, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy can lead to improvement of severe forms of B cell mediated autoimmune disease including…
Abstract Number: 0893 • ACR Convergence 2023
Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model
Trine Jorgensen and Lindsey Han, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can cause damage to multiple organs, including the kidneys in Lupus Nephritis (LN). Current treatments…
Abstract Number: 0913 • ACR Convergence 2023
Neutrophils in Patients with Systemic Lupus Erythematosus Show Pronounced Inflammatory Signals
Annie Law¹, Chee Jian Pua², Dianyang Guo³, Chin Teck Ng⁴, Julian Thumboo¹, Andrea Hsiu Ling Low⁵ and Xiubo Fan¹, ¹Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²National Heart Centre, Singapore, Singapore, ³Singapore General Hospital, Singapore, Singapore, ⁴Singapore General Hospital; Duke-NUS Medical School, Singapore, Malaysia, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: IFN response, plasmablasts and neutrophils are three hallmarks of systemic lupus erythematosus (SLE). Studies showed that the netting neutrophils stimulated plasmacytoid dendritic cells to…
Abstract Number: 0933 • ACR Convergence 2023
The ‘Sweet’ in Lupus – IgG Glycosylation in Lupus Nephritis
Rhea Bhargava¹, Rohit Upadhyay², Scott Wenderfer³, Jing Chen² and George Tsokos⁴, ¹Tulane University, New Orleans, LA, ²Tulane University School of Medicine, New Orleans, LA, ³University of British Columbia, Vancouver, BC, Canada, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Lupus nephritis (LN) occurs in 50% of patients with systemic lupus erythematosus (SLE) for which we lack biomarkers, and an understanding of its pathogenesis.…
Abstract Number: 1230 • ACR Convergence 2023
Differences in Nailfold Capillary Morphology Distinguish Juvenile Dermatomyositis Patients That Are Myositis-Specific Autoantibody Positive
Nicholas McClellan, Sarah Vandenbergen, Sophia Matossian, J. Michelle Kahlenberg and Jessica Turnier, University of Michigan, Ann Arbor, MI
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by multiorgan vasculopathy, and degree of vasculopathy can indicate more severe disease. Nailfold capillaroscopy is a non-invasive method to…
Abstract Number: 1359 • ACR Convergence 2023
Association of Menstrual Cycles and Disease Flare Activity in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Lucy Masto¹, Amaya Smole¹, Caroline Siegel¹, Sarah Lieber², Sanjana Adurty³, Jonah Levine¹, Bessie Stamm¹, Lisa Mandl², Michael Lockshin², Lisa Sammaritano² and Medha Barbhaiya², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Weill Cornell Medical College, New York, NY
Background/Purpose: Whether the timing of menstruation impacts disease activity or severity among women with SLE or RA is poorly understood. We evaluated systemic rheumatic disease…
Abstract Number: 1455 • ACR Convergence 2023
Risk Factors of Cytomegalovirus Reactivation and Disease in Patients with Systemic Lupus Erythematosus
Miyu Wakatsuki¹, Hiroyuki Yamashita¹, Yuuya Akiyama¹, Setsuko Oyama¹, Shintarou Aozaki¹, Ryo Kuwata², Misa Yamaji¹, Takuya Harada¹, Kyouko Motomura¹, Yuusuke Nakamichi¹ and Hiroshi Kaneko³, ¹National Center for Global Health and Medicine, Tokyo, Japan, ²Department of Rheumatology, National Center for Global Health and Medicine, Tokyo, Japan, ³Division of Rheumatic Disease, National Center for Global Health and Medicine, Tokyo, Japan
Background/Purpose: Cytomegalovirus (CMV) infection is classified as an opportunistic infection that occurs in autoimmune diseases. Systemic lupus erythematosus (SLE) is one of the most frequently…
Abstract Number: 1472 • ACR Convergence 2023
Prevalence of Hepatic Injury in Patients with Systemic Lupus Erythematosus: A 28-Year Single Center Experience
Asif Hitawala¹, Zerai Manna², Yenealem Temesgen-Oyelakin³, Elaine Poncio³, Christopher Koh⁴, sarfaraz Hasni² and Theo Heller⁴, ¹NIDDK/NIH, Bethesda, MD, ²Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴NIDDK/Liver disease branch, Bethesda, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are known to have hepatic injury (HI), however large-scale longitudinal studies are lacking.We report our experience of HI…
Abstract Number: 1489 • ACR Convergence 2023
Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell–related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study
Marie-Claude Gaudreau¹, James Fann¹, Alan Friedman¹, Thierry Sornasse¹ and Joan Merrill², ¹AbbVie, Inc., North Chicago, IL, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: B-cell hyperactivity (1) is a hallmark of the disordered immunity of SLE, arising in the context of a complex array of innate and adaptive…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].